Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
2023 · New England Journal of Medicine · 469 citations
https://doi.org/10.1056/nejmoa2312054
C
Cyrille Hulin
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
308
Papers
12.9K
Citations
45
h-index
116
i10-index
Cyrille Hulin is an academic researcher from Sciences Po Bordeaux. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & Protein Degradation and Inhibitors & Peptidase Inhibition and Analysis. The author has an h-index of 45, co-authored 262 publications.
ORCID: 0000-0002-3749-5161Papers by this author
worksA simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
2019 · Leukemia · 221 citations
https://doi.org/10.1038/s41375-019-0539-0
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
2024 · Nature Medicine · 87 citations
https://doi.org/10.1038/s41591-024-03050-2
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial
2018 · Leukemia · 71 citations
https://doi.org/10.1038/s41375-018-0133-x
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma
2025 · New England Journal of Medicine · 40 citations
https://doi.org/10.1056/nejmoa2505133
Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study
2023 · Annals of Hematology · 8 citations
https://doi.org/10.1007/s00277-023-05278-3
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat